InSite Vision is an ophthalmic company primarily focused on developing therapies that treat ocular infection and inflammation, glaucoma, and retinal diseases. InSite Vision's lead product is AzaSite^®, a topical anti-infective which targets infections of the eye, which was approved by the FDA in April 2007. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite^®, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician.

AzaSite was commercially launched in the United States in the late third quarter of 2007 and is licensed to Inspire Pharmaceuticals, a wholly owned subsidiary of Merck & Co.(NYSE:MRK). InSite Vision plans to pursue additional commercial partnerships to address AzaSite market opportunities outside the U.S. and Canada.

The Company will continue to build on its azithromycin/DuraSite technology platform by developing AzaSite Plus as its follow-on product to AzaSite. AzaSite Plus is an antibiotic and corticosteroid combination product, where the antibiotic inhibits ocular bacterial proliferation, while the corticosteroid allows suppression of the inflammatory response.